Verrica Pharmaceuticals VRCA shares are trading lower after the company announced the FDA issued a Complete Response Letter regarding its New Drug Application for VP-102 for the treatment of molluscum contagiosum.
Verrica Pharmaceuticals' stock has been falling Tuesday, down 16.37% to a price of $10.06. Tuesday the stock has been traded at a volume of 972.46 thousand, about 747.07% of its recent 30-day volume average of 130.17 thousand.
The moving average price of the stock over the past 50 days was $11.11 at the time this article was published. In the past fifty-two weeks, the stock price has been as high as $18.42 and as low as $7.05.
Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
